PARP Inhibitors (Olaparib/Lynparza)

Type: drug

Status: FDA/EMA Approved

Developer: AstraZeneca

Breakthrough Summary

No summary available.

Mechanism of Action

Blocks DNA repair in BRCA-mutant tumors

Year: 2018+